Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.384
Neutral
RSI(14)
61.525
Neutral
STOCH(KDJ)(9,3,3)
43.210
Buy
ATR(14)
0.497
High Vlolatility
CCI(14)
376.373
Overbought
Williams %R
36.533
Buy
TRIX(12,20)
-2.886
Sell
StochRSI(14)
100.000
Buy
Ensysce Biosciences Inc
ENSCView Detailed Chart
3.670USD
+1.799+96.26%
Close 04/23, 16:00（ET）Quotes delayed by 15 min
4.98MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+96.26%
5 Days
+63.84%
1 Month
+6.38%
6 Months
-54.61%
Year to Date
-54.91%
1 Year
-54.78%
View Detailed Chart
Agency Rating
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Neutral
Moving Average
Indicators
Value
Direction
MA5
2.168
Buy
MA10
2.082
Buy
MA20
2.326
Buy
MA50
3.842
Sell
MA100
5.658
Sell
MA200
5.914
Sell
News
More news coming soon, stay tuned...
Company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Company codeENSC
CompanyEnsysce Biosciences Inc
CEODr. Lynn D. Kirkpatrick, Ph.D.
Websitehttps://ensysce.com/
